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ABSTRACT

The Effects Of Low Frequency Ultrasound
In Transdermal Drug Delivery

Aaron M. Wells
Department of Exercise Sciences
Doctor of Philosophy

Objective: Determine if varying ultrasound frequency affects the delivery of 10%
hydrocortisone concentrations during phonophoresis. Utilize intramuscular microdialysis
probe for drug collection, thus improving the experimental model. Methods: Thirty one
(10 in groups 1 and 2, 11 in group 3) healthy subjects participated in this study.
Interventions: Subjects were randomly assigned to one of three treatment groups
receiving 10 minute ultrasound treatments applied to a standardized area of the
gastrocnemius muscle of the right leg. The ultrasound was performed over the treated
area using a 10% hydrocortisone compound mixed with standard ultrasound gel. The
contralateral limb served as the control (no mixed compound or treatment) for all groups.
Group one received sham ultrasound. Medicated gel was placed on the treatment site, the
sound head moved, but no ultrasound was applied. Group two received 45 KHz at .056
w/cm2. Group three received 1 MHz at 1.0 w/cm2 at a 50 % duty cycle. Results: There
was no difference in cortisol concentration change during treatment between the three
treatment groups on the treated limbs (sham = 1.1 ± 7.5 ng/ml, 45 KHz = 1.1 ± 1.5 ng/ml,
1 MHz = 4.1 ± 7.8 ng/ml; F2,22 = .34, P = .72) or control limbs (sham = 1.65 ± 6.6 ng/ml,
45 KHz = -1.3 ± 2.7 ng/ml, 1 MHz = 0.37 ± 8.1 ng/ml; F2,22 = .67, P = .546). No
difference was found in cortisol concentration change during treatment between the
treatment limbs and the control limbs (treatment = 2.1 ± 6.2 ng/ml, control = 0.20 ± 5.9
ng/ml; F1,22 = .9, P = .35). The following factors were found to influence cortisol
concentrations levels in dialysate collected during treatment: depth of muscle in the
treatment limbs (F1,22 = 6.4, P = .02), microdialysis probe depth in the control limbs (F1,22
= 4.1, P = .05), and pre treatment cortisol level in the control limbs (F1,22 = 10.1, P = .004.
Conclusions: There was no evidence altering ultrasound frequency from 45 KHz to 1
MHZ enhanced the delivery of 10% hydrocortisone to treatment tissues under these
experimental conditions.

Keywords: microdialysis, 10% hydrocortisone
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Abstract
Objective: Determine if varying ultrasound frequency affects the delivery of 10%
hydrocortisone concentrations during phonophoresis. Utilize intramuscular microdialysis probe
for drug collection, thus improving the experimental model. Methods: Thirty one (10 in groups
1 and 2, 11 in group 3) healthy subjects participated in this study. Interventions: Subjects were
randomly assigned to one of three treatment groups receiving 10 minute ultrasound treatments
applied to a standardized area of the gastrocnemius muscle of the right leg. The ultrasound was
performed over the treated area using a 10% hydrocortisone compound mixed with standard
ultrasound gel. The contralateral limb served as the control (no mixed compound or treatment)
for all groups. Group one received sham ultrasound. Medicated gel was placed on the treatment
site, the sound head moved, but no ultrasound was applied. Group two received 45 KHz at .056
w/cm2. Group three received 1 MHz at 1.0 w/cm2 at a 50 % duty cycle. Results: There was no
difference in cortisol concentration change during treatment between the three treatment groups
on the treated limbs (sham = 1.1 ± 7.5 ng/ml, 45 KHz = 1.1 ± 1.5 ng/ml, 1 MHz = 4.1 ± 7.8
ng/ml; F2,22 = .34, P = .72) or control limbs (sham = 1.65 ± 6.6 ng/ml, 45 KHz = -1.3 ± 2.7 ng/ml,
1 MHz = 0.37 ± 8.1 ng/ml; F2,22 = .67, P = .546). No difference was found in cortisol
concentration change during treatment between the treatment limbs and the control limbs
(treatment = 2.1 ± 6.2 ng/ml, control = 0.20 ± 5.9 ng/ml; F1,22 = .9, P = .35). The following
factors were found to influence cortisol concentrations levels in dialysate collected during
treatment: depth of muscle in the treatment limbs (F1,22 = 6.4, P = .02), microdialysis probe depth
in the control limbs (F1,22 = 4.1, P = .05), and pre treatment cortisol level in the control limbs
(F1,22 = 10.1, P = .004. Conclusions: There was no evidence altering ultrasound frequency from

3
45 KHz to 1 MHZ enhanced the delivery of 10% hydrocortisone to treatment tissues under these
experimental conditions.
Keywords: microdialysis, 10% hydrocortisone
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Introduction
Medication is commonly used in treating musculoskeletal injury.1, 2 There are many
concerns however, regarding effective and appropriate dosage delivery methods.2-4 Long term
use of some orally ingested medicines can result in damage to the liver, kidneys, and stomach.3-7
Injected medication can result in excessive patient discomfort, infections, nerve damage, and
scar tissue in repeat injection sites.6 Questions arise as to the dosage required to ensure adequate
treatment following first pass through the digestive system, and in the amount of actual drug
delivery reaching the target tissues.1,3, 8-10 These concerns and rising costs in developing new
drugs, have contributed to the exploration of alternative methods of drug delivery. Transdermal
drug delivery is one such method.
Transdermal drug delivery (TDD) is the administering of medication through the intact
skin. It is designed to facilitate more efficient delivery while decreasing many of the
complications that arise with traditional drug therapy.1, 3 Examples of TDD techniques include
iontophoresis, medicated skin patches, topical ointments, and phonophoresis, the use of
ultrasound waves to facilitate drug delivery.
The therapeutic mechanisms of ultrasound are classed in two categories: thermal and
mechanical. The thermal effects and benefits of ultrasound are well documented.4-6 However,
the mechanical or non-thermal effects have a much greater influence on TDD.11-13 It is these
cellular level mechanical phenomena that result in increased skin permeability, thus permitting
greater drug delivery to desired tissues.
Unfortunately, despite frequent use of phonophoresis, the literature is inconclusive
regarding its effectiveness.9, 14-20 Much of this disparity is due to two factors: first, questions
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regarding appropriate application parameters (i.e., treatment duration, duty cycle, and wave
frequency) and second, the lack of an objective method to analyze actual drug delivery.19, 21-32
The following research questions directed this study: Does altering ultrasonic frequency
enhance the delivery of cortisone (using 10% hydrocortisone cream)? Do pre-treatment cortisol
levels, depth to the treated muscle, and depth of the microdialysis collection probes influence the
analysis determining if drug delivery occurred?
Methods
Subjects
Thirty-one healthy college students were recruited. Subjects were both male and female
with no preference given to gender. Due to excessive variations of cortisol levels that occur
during menstruation, female participation was limited to those currently in the first seven days of
the menstrual cycle. Prior to inclusion, each subject completed an information and health and
history questionnaire. Persons experiencing a lower extremity injury or general illness within
two weeks of their participation in this study, or who had a history of decreased sensation within
the last year to the lower legs were excluded.
Study Design
A 2 X 2 X 3 mixed factor design with repeated pre and post measurements guided data
collection. Independent variables were time (pre and post treatment), treatment (treated and
control), and ultrasound level (sham, 45 KHz, and 1 MHz). The dependant variable was dialysate
cortisol level. In addition, the depth of the microdialysis probe (PD) and the depth of the treated
muscle (MD) were measured prior to the experiment with Doppler imaging ultrasound.
Drug delivery was determined by measuring cortisol levels in dialysate collected from
interstitial fluid prior to and following treatment. Subjects were assigned to one of three
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treatment groups. The right leg always received the treatment while the left leg served as a
control (no hydrocortisone cream or treatment).
Instruments
Ultrasound Devices and Medicated Cream. The 1 MHz ultrasound and sham ultrasound
applications were applied with an Omnisound 3000 E Ultrasound device (Accelerated Care Plus,
Reno, NV) with a 7.2 cm diameter sound head with 5 cm2 crystal at an intensity of 1.0 W/cm2
with a 50% duty cycle to equate treatment of acute injury. The 45 kHz ultrasound treatment was
applied with a Duo Son ultrasound device (S.R.A. Developments Ltd, South Devon, United
Kingdom) at an intensity of .058 W/cm2 per machine pre-set intensity.
Aquasonic 100 water soluble hypoallergenic ultrasound transmission gel (Parker
Laboratories, Inc, Fairfield, NJ) was mixed with hydrocortisone to create a 10% hydrocortisone
cream. This cream was prepared by the University Student Health Center Pharmacy.
Ultrasound Imaging Device. A Titan Ultrasound System (SonoSite, Bothell, WA) was
used to measure treated muscle depth and microdialysis probe depth following insertion.
Intramuscular Microdialysis Probe
Probe Construction. The microdialysis probe was custom made of static, non-moving
components that illicit no reaction to human tissue. Production of the probes was performed
under a microscope to ensure proper production and structural integrity. A 37 cm length of
spring tempered stainless steel wire (0.002 inch diameter, Alan Baird Ind., NJ) supported the
probe during construction and facilitated insertion into the treatment site. The probe consisted of
an 8 cm piece of polyimide tubing, 4 cm of hollow fiber dialysis tubing, 4 cm of polyimide
tubing, 20 cm of PE 10 tubing, and 6 cm of PE 50 tubing (Figure 1). The 8 cm piece polyimide
tubing (0.0064 inch OD, Cole-Parmer, IL) was inserted 1 cm into the hollow fiber tubing and
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secured with standard super glue on each end leaving 2 cm of exposed membrane. The
completed probe was checked for proper production by passing sterile saline solution through the
device to make certain no joints or portions of the probe leaked. Following the testing, probes
were packaged individually and gas sterilized with ethylene oxide.
Probe Recovery Analysis. Invitro recovery property of the probes was determined by
calculating the extraction fraction. To obtain that value, the probe, including the portion
containing the hollow fiber, was placed in a shallow tub and bathed in 2 ml of 0.9% saline. The
bath was thoroughly mixed while one end of the probe collected samples and the other was
attached to the infuser. The probe was perfused at 5.0 µl/min with 0.9% saline. After an
equilibration period of 60 minutes, a known quantity of cortisol was added to the bath. Dialysate
samples of 100 µl were collected 8 times (every 20 minutes for 160 minutes) to establish a
steady state recovery rate for microdialysis probes. The extraction fraction was calculated by
dividing the cortisol concentration in the dialysate by the cortisol concentration in the bath. The
invitro recovery rate of the microdialysis probes was 33 ± 3 % of cortisol added to the solution.
Tissue Perfusion. Probes were perfused using a Harvard Apparatus PHD 2000
Programmable Infusion Pump (Harvard Apparatus, Holliston, MA).
Drug Delivery Analysis. The amount of cortisol in dialysate collected from the intramuscular
microdialysis probe was measured with a cortisol enzyme immunoassay (Immuno Biological
Laboratories, Hamburg, Germany, ninety-six well microtiter plate). Cortisol levels are reported
in ng/ml.
Testing Procedures
Subjects were placed in a prone position. The treatment and control sites, located in the medial
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gastrocnemius proximal to the Achilles tendon on the left and right limb, were cleansed and
sterilized.
Probe Placement. Using a 27-gauge needle used as a guide cannula, probes were
inserted horizontally into the medial gastrocnemius muscle approximately 2 inches superior to
the musculotendinous junction of the Achilles tendon in both the treated and control limb.
The probe entrance and exit sites on the skin were at least 6.0 centimeters apart. Cannula
depth, muscle penetration and depth of the treated muscle were verified and recorded (cm) at
both the treatment and control sites with Doppler ultrasound imaging. After confirming the
cannula had penetrated the muscle at both the treatment and control sites, the microdialysis
probes were fed through the guide cannula. Following insertion of the probe, the cannula was
removed with the probes left in place. Small vials were secured with tape at the ends of the
microdialysis probes near the exit sites to collect dialysate.
The probes were perfused with 0.9% sterile saline at a rate of 10µl/min with a Harvard
infusion pump for 70 minutes. This allowed tissue to recover from needle and probe insertion.
During the first five minutes, the volume of dialysate (fluid coming out of the probe) was
monitored. If this volume was significantly lower than expected (indicating a leak) the probe
was replaced. At minute 70 of the recovery period the infusion rate was altered to 5µl/min and
remained constant for the remainder of the experiment. Dialysate was then collected for 20
minutes to determine pre-treatment cortisol levels. After 20 minutes of collecting dialysate, the
vials were replaced. The vials with dialysate were labeled and stored in a freezer for future
analysis.
Drug Delivery Treatment. We then placed a pre fabricated template to confine the
treatment area and ensure consistent treatment size, an area 2 times the size of the 5 cm
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ultrasound head (a circle with a 5 cm radius). We then placed the prepared 10 % hydrocortisone
coupling gel on the treatment site of the treated limb (Figure 2).
The ultrasound head was moved in circular pattern for the duration of the 10-minute
treatment at a rate of approximately 4 cm per second. During the treatment, dialysate from the
intramuscular microdialysis probe was collected from both the treatment and control sites for
analysis.
At the conclusion of the 10 minute treatment, the medicated cream was carefully
removed. Subjects remained in the prone position for an additional 10 minutes while dialysate
collection continued to ensure that medication delivered during the ultrasound treatment had
passed to the vials. After 10 minutes the saline perfusion was terminated and the collection vials
were removed, labeled, and stored in a freezer for later analysis. Then we removed the
ultrasound template and the intramuscular microdialysis probes. The portal sites were treated
with triple antibiotic and covered with a band aid. Subjects were given a basic wound care guide
with contact information should any questions arise.
Statistical Analysis
We used a General Linear Model incorporating analysis of covariance and repeated
measures to determine if cortisol change was different between the groups. A 2 X 3 ANCOVA
with groups (control and treated) and treatment (sham, 45 KHz, 1 MHZ) with repeated measures
on treatment was used. Change in cortisol levels was computed by taking the difference between
the dialysate cortisol levels collected before and following treatment. Depth to muscle (MD),
probe depth (PD), and pre-treatment dialysate cortisol concentrations (PreC) for both the
treatment (Tx) and control (C) were used as covariates in the model. For all differences, the
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level of significance was set at P < .05. Data were analyzed using SPSS software (Statistical
Package for the Social Sciences, version 17).
Results
Dialysate cortisol concentrations collected from interstitial fluid within the muscle were
not affected by treatment or site. No significant difference in dialysate cortisol concentration
change was found between treatment groups in the treated limb (Table 1; sham = 1.1 ± 7.5
ng/ml, 45 KHz = 1.1 ± 1.5 ng/ml, 1 MHz = 4.1 ± 7.8 ng/ml; F2,22 = .34, P = .72). No significant
difference in dialysate cortisol concentrations during treatment was found when comparing the
treated limbs and control limbs (treatment = 2.1 ± 6.2 ng/ml, control = 0.20 ± 5.9 ng/ml; F1,22 =
.9, P = .35).
The results indicate that the depth of the muscle (MD) in the treatment group influenced
dialysate cortisol concentration change (0.27 ± .06 cm; F1,22 = 6.4, P = .02). The results also
indicate that the depth of the microdialysis probe (PD), inserted 1.23 ± .24 and 1.31 ± .23 cm in
the control and treated limbs, respectively, influenced cortisol level change from the dialysate
collected following treatment in the control group but not in the treatment group (control, F1,22 =
4.1, P = .05; treatment, F1,22 = .78, P = .39).
Furthermore, the dialysate cortisol levels prior to treatment influenced cortisol level
change observed in the collected dialysate immediately following treatment in the control but not
treated site (control = 15.8 ± 4.9 ng/ml, F1,22 = 10.1, P = .004; treated = 16.0 ± 3.5 ng/ml, F1,22 =
1.1, P = .31). The average dialysate cortisol concentrations following treatment in the control
limbs and treatment limbs were 16.0 and 18.1 ng/ml, respectively.
Discussion
The lack of change in cortisol level following treatment with 45KHz and 1 MHz
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ultrasound is in agreement with others.19,30 Kuntz et al30 reported similar results in a recent study
comparing 1 MHz ultrasound with sham when attempting to deliver 10% hydrocortisone. Bare,19
also attempting to deliver 10% hydrocortisone, reported no significant delivery following a
similar treatment protocol.
Despite the outcomes of these studies, many authors are of the opinion phonophoresis is
an effective tool for transdermal drug delivery.15,18,21-24 Studies as early as 1954 by Fellinger and
Schmid36 indicated ultrasound could transport hydrocortisone for treatment of injury. Kleinkort
and Wood22 determined transdermal delivery of hydrocortisone was possible following his study
in which ultrasound was used to treat various joints of the body. Griffin9,10,16 furthered the
discussion reporting successful delivery of hydrocortisone in studies using human subjects and
swine tissue. More recently, Pribicevic28 reported phonophoresis with 1% hydrocortisone cream
was successful in treating shoulder injury when used in conjunction with massage and joint
mobilization.
The literature appears to be inconclusive as to the effectiveness of transdermal drug
delivery. However, a closer examination reveals the major difference between studies reporting
drug delivery and those indicating no delivery occurred are the methods utilized by researchers
to measure and determine the effectiveness of phonophoresis (Table 2).
Every author but one reporting drug delivery of hydrocortisone relied upon a clinical
evaluation to determine success. Griffin9,10,16,24 reported successful delivery of hydrocortisone
through tissue analysis. However, delivery was determined utilizing chemical analysis of the
swine tissue following treatment and a clinical evaluation was used following treatment in
human subjects. Byl21 too, reported drug delivery in swine tissue following ultrasound, but he
delivered dexamethasone, a drug with a different molecular size. Kleinkort and Wood22 relied
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upon a clinical evaluation to determine if drug delivery had occurred. Patients reported feeling
better or worse and functional tests were performed with advances credited to the treatment.
Researchers using an objective measure to determine drug delivery have not shown
phonophoresis to effective. Bare 19 reported no treatment affect when they analyzed blood serum
to evaluate increased levels of cortisol following treatment with 10% hydrocortisone cream.
Utilizing the same treatment compound but examining cortisol levels in tissues from biopsies
performed following treatment, Kuntz et al30 also reported no treatment effect.
With the obvious correlation in methodology between studies reporting success and those
indicating another result one could conclude phonophoresis does not facilitate actual transdermal
drug delivery. Literature indicating delivery based upon methods other than chemical analysis
could see patient improvement simply as a result of the application of ultrasound or time spent
with the clinician. However, it is also possible the differences in reported outcomes are a result
of the difficulty for researchers to accurately measure drug delivery.
Our ability to assert claims based upon detected cortisol levels was greatly affected by
two factors: large variance between subjects and decreased power or small sample size in our
analysis. Multiple subjects in each group demonstrated cortisol increases in either the control or
the treatment limb during treatment. Multiple subjects in each group also demonstrated
decreases in cortisol in collected dialysate in either the control or treatment limb. Studies in
which results are varied as these can attempt to clarify results through increased testing of
subjects. 30
This variation could also be a result of the test used to evaluate drug delivery. For this
study we utilized a cortisol enzyme immunoassay. The results of each assay were closely
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analyzed. Standards contained in each sample kit to verify proper function of cortisol analysis
were within anticipated range.
We also must consider our use of the microdialysis probe to collect dialysate. This is the
first study of transdermal to utilize microdialysis. While testing of probes was done in vitro to
determine expected outcomes, in vivo studies can affect outcomes by introducing differences
among subjects. Consideration of subject variance, and attempting to control and decrease that
variance, is essential.
The second purpose of this study was to evaluate how results are determined, developing
a more sophisticated model through which we may more accurately assess drug delivery. This
appears to be the first study to evaluate and control for all of the following parameters: pretreatment cortisol levels in the target tissue, adipose thickness over the target tissue, and the
exact depth from where cortisol measurements were taken; all of which proved to be significant
factors in evaluating cortisol level change following treatment.
It is also necessary to decrease variance by controlling for these factors experimentally as
well as statistically. With cortisol levels changing throughout the day it is necessary to begin
testing with stable pre-level measurement. Normal plasma cortisol levels range from 50 to 230
ng/ml in the morning and can decrease to 30 to 150 ng/ml in the afternoon.37 Several factors
such as stress, diet, and fitness level can also strongly vary cortisol levels between subjects.38 It
is therefore recommended that testing be done on all subjects at approximately the same time of
morning and minimizing the amount of activity and diet each subject will have experienced prior
to reporting to the lab. The ability to analyze cortisol levels immediately prior to testing through
a minimally invasive method also enables us to make more definitive conclusions about the
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amount of drug actually being delivered through the skin. Microdialysis probes permit this
testing.
Understanding sound waves and their reaction to certain mediums can further explain the
need to monitor and control depth, not only from where we are taking measurements, but to the
target tissue itself. As sound waves pass through tissues they decrease in energy, or attenuate, as
a result of absorption of the sound wave.39 Through Doppler imaging we were able to determine
exact adipose tissue thickness and probe depth, providing a clearer analysis and explanation of
expected sound wave activity. Subjects should be reasonably similar in adipose thickness over
the treatment site to be used. If possible, collection depth should be similar in all subjects,
minimizing variable attenuation of the soundwaves.
The frequency and intensity of ultrasound utilized during the experiment should also be
monitored. Two main factors should be considered when determining ultrasound parameters:
desired depth of soundwave penetration and tissue temperature. Lower ultrasound frequency is
utilized for deeper tissues.40 To ensure optimal soundwave depth, we utilized 1 MHz and 45
KHz. The intensity of the soundwave can directly affect the temperature of the treated tissue.
Temperature increase in tissue can increase blood flow.41 When utilizing ultrasound for TDD,
increased blood flow in target tissues can decrease the ability of the desired medication to reach
target tissues. As the medication passes the stratum corneum of the skin, increased blood flow
can cause the drug to be taken into the blood stream more rapidly before reaching target tissues.
This study utilized 1.0 w/cm2 with the 1 MHz treatment and 0.56 w/cm2 with the 45 KHz
treatment, intensities specifically aimed to reduce increased blood flow for the treatment of acute
injury.

15
Conclusion
In contrast to some previous studies yet comparable to others evaluating transdermal drug
delivery, under the conditions of this study we detected no change in cortisol level due to
treatment using 10% hydrocortisone cream. Our data does suggest that measuring cortisol levels
prior to treatment, depth to the treated muscle, and the depth of the collection site can provide a
clearer evaluation of efficacy of transdermal drug delivery.
Future studies involving phonophoresis should control for variance by using statistical
control methods as this study does employing a General Linear Model with covariate analysis.
In addition, future studies should control for variation experimentally in the following ways:
First, researchers should understand the nature of ultrasound waves and their physiologic affect
on various types of tissue, ensuring that the parameters including frequency, intensity, and time,
are appropriate to achieve the desired affect. Second, one must not only monitor, but control the
depth of the dialysis probe, understanding that increased adipose thickness as well as depth of
collection does affect the ability of the researcher to accurately measure the delivered drug. And
lastly, consider that factors such as time of day, stress, and fitness level can affect cortisol levels
in the body.
Despite the inconsistencies in the literature, phonophoresis continues to be commonly
used in treating musculoskeletal injury. Before a researcher or health care professional should
accept or repudiate findings, it is important to understand possible explanations as to why
discrepancy exists. Further studies are needed before definitive conclusions can be stated.
However, understanding the sources of variation in measurement, testing, and evaluation can
continue to improve, providing greater power and precision in the experimental results.
.
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Table 1. Descriptive Statistics (N=31)_________________________________________
_____________________________________________________________________________________

Sham
45 KHz
1 MHz
________________________________________________________________________
Control
Pre Cortisol (ng/ml) 14.2 ± 4.4
16.6 ± 3.1
16.5 ± 6.9
Post Cortisol (ng/ml) 15.8 ± 5.6
15.3 ± 2.9
16.9 ± 4.6
Change* (ng/ml)
1.6 ± 6.6
-1.3 ± 2.2
0.4 ± 8.1
Muscle Depth (cm)
Probe Depth (cm)

0.27± 0.07
1.13± 0.19

0.27± 0.03
1.27± 0.27

0.27± 0.04
1.29± 0.24

16.1 ± 2.9
17.2 ± 4.0
1.1 ± 1.5

15.9 ± 3.1
19.9 ± 7.6
4.1 ± 7.8

0.28± 0.1
1.38± 0.25

0.27± 0.03
1.25± 0.27

0.27± 0.03
1.33± 0.15

Range
Control
Pre Cortisol (ng/ml) 23.7 – 10.4
29.9 – 11.0

20.2 – 12.4
20.3 – 12.0

34.2 – 10.1
26.0 – 11.6

Treated
Pre Cortisol (ng/ml) 16.2 ± 4.6
Post Cortisol (ng/ml) 17.3 ± 6.7
Change* (ng/ml)
1.1 ± 7.5
Muscle Depth (cm)
Probe Depth (cm)

Treated
Pre Cortisol (ng/ml) 28.2 – 11.7
20.6 – 11.8
21.5 – 12.4
Post Cortisol (ng/ml) 34.7 – 10.4
24.4 – 11.8
35.4 – 11.6
________________________________________________________________________
*Change is the difference between pre-treatment cortisol and post treatment cortisol
measurement
± represents standard deviation
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Table 2. Previous In Vivo Phonophoresis Studies
Author
Oziomek27
1991

Medicine
Delivered
Myoflex

Treatment
Parameters
1 MHz 1.5 w/cm2
5 minutes

Area
Treated
Right
Anterior
Forearm

Measure Used to
Verify Delivery
Serum Salicylate
Concentration / Blood
Draw

Affective
Y/N

Forearm

Serum Cortisol
Concentration / Blood
Draw

N

Left
Forearm

Blood Draw

N

Bare19
1996

10% Hydrocortisone

1 MHz 1.0 w/cm2
5 minutes

Darrow29
1999

Dexamethasone

1 MHz 1.0 w/cm2
5 minutes

Kozanoglu26
2003

5% Ibuprofen Cream

1 MHz 1.0 w/cm2
5 minutes

Knee Joint

Clinical Evaluation

N

Kuntz30
2006

10% Hydrocortisone

1 MHz 1.0 w/cm2
7 minutes

Vastus
Lateralis

Tissue Biopsy

N

Kleinkort22
1975

10% Hydrocortisone

1 MHz 1-1.5 w/cm2
6 minutes

Various
Structures

Clinical Evaluation

Y

Griffin24
1980

10% Hydrocortisone

1 MHz 1.5 w/cm2
5 minutes

Various
Structures

Clinical Evaluation

Y

Wing23
1982

10% Hydrocortisone

1 MHz 1.0 w/cm2
8 minutes

TMJ
Joint

Clinical Evaluation

Y

Byl21
1993

Dexamethasone

1 MHz 1.5 w/cm2
5 minutes

In Vivo
Swine
Tissue

Tissue Biopsy

Y

Pribicevic28
2005

1% Cortisone

Not specified

Shoulder

Clinical Evaluation

Undetermined

N
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Figure 1. Schematic of Microdialysis Probe Used for Collection
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Figure 2. Medicine Application Over Treatment Site

24

Appendix A
Prospectus
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Chapter 1
Introduction

The use of medication in treatment protocols of musculoskeletal injury is a very common
practice. However, with the use of various medications comes potential side affects. Long term
use can result in organ damage as drugs are ingested, such as to the liver, kidneys, and stomach.
Infections and excessive patient discomfort can occur during injection, as well prevalence of scar
tissue build up in repeat injection sites. Questions arise as to the appropriate dosage amount to
ensure adequate treatment following first pass through the digestive system, not to mention
uncertainty in the amount of actual drug delivery reaching the target tissues. Alternative
methods of drug delivery which can provide the patient with more effective and efficient means
of medication are commonly explored. Transdermal delivery is one such method. Transdermal
drug delivery is utilized to ease the complications that can occur with other drug delivery
mechanisms.1 Iontophoresis, medicated skin patches, and topical ointments are examples of
frequently utilized transdermal drug delivery mediums. While the use of these tools is common,
questions continue to arise regarding their efficacy. Researchers disagree in the amount of drug
delivery to target tissues, patient response, and overall effectiveness of these methods.1-23
Phonophoresis, the use of ultrasound waves to deliver medication through the skin, is
another frequently used method of transdermal medicine delivery.4 However, it too, despite
frequent application, contains many questions regarding its parameters of use including treatment
duration, wave frequency, and overall effectiveness in delivering medication.
The use of sound waves propagated by ultrasonic devices as a therapeutic modality for
the treatment of musculoskeletal trauma has been practiced for more than fifty years.23 The
variety of conditions for which ultrasound treatment is clinically used includes ligament, sprains,
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muscular injury, inflamed tendons and tendon sheaths, lacerations, excessive scar tissue,
inflamed and damaged joint capsules, bone regeneration and healing, delayed onset muscle
soreness, and most recently thrombolysis.24 The therapeutic benefits of ultrasound are classed
into two categories: thermal and non-thermal. While the thermal effects and benefits of warming
tissues are well documented, equally beneficial yet often overlooked and frequently
misunderstood are the non-thermal or mechanical effects received during an ultrasound
treatment.23-26 Two common mechanical effects of ultrasound are cavitation, the expansion and
contraction of cells when reacted upon by propagated sound waves, and acoustic streaming, the
displacement of particles within and adjacent to the cell as a result of the ultrasound beam flow.24
It is via the mechanical effects of ultrasound that the drug delivery is reported to occur.
These effects can alter cell wall permeability and cell function.24 The rate of expansion and
contraction of the cell, or cavitation, varies depending upon the frequency of the sound waves.
Traditional ultrasound devices operate at frequencies of 1 MHz and 3 MHz. Phonophoresis for
drug delivery typically utilizes the 1 MHz frequency treatment. However, as cellular expansion
and contraction is increased, as opposed to rapid oscillation, the permeability of the cell wall is
increased. This altered permeability, in conjunction with continuing acoustic streaming of
particles, could affect the drug delivery rate during phonophoresis treatments.
Effective examination of drug amounts within the tissue during and following treatments
could not only indicate success in delivery of desired medicine, but further explain mechanical
effects on cellular function when utilizing ultrasound as a therapeutic modality. It is therefore
important to evaluate what affect varying ultrasound frequency has on cellular permeability and
function in effective transdermal drug delivery and how that delivery could be attributed to
mechanical affects of ultrasound therapy.
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Research Questions
1.

Does altering ultrasound frequency affect transdermal drug

delivery into muscle tissue?
2.

Can this increased drug delivery be explained by non-thermal or

mechanical effects of ultrasound in alteration of cell permeability
and cellular function?
Research Hypotheses
The following hypotheses will guide this study.
1.

Varying ultrasound frequency will alter transdermal drug

delivery rate and depth of medicine into muscle.
2.

Decreasing ultrasound frequency will increase drug

delivery rate of medicine across the skin and into muscle.
3.

Increased transdermal medicine delivery will occur at

decreased ultrasound frequencies via mechanical properties
of ultrasound therapy, including cellular cavitation and
acoustic streaming.
Operational Definitions
Absorption – To take in, suck up, or imbibe.70
Acoustic Streaming – Physical forces of the sound waves that provide a
driving force capable of displacing ions and small particles.24
Active Delivery Systems – Delivery systems in that require a physical
force to facilitate the movement of drug molecules across the skin.32
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Cavitation – The physical forces of the sound waves on microvenvironmental
gases with fluid.24
Capillary – Any of the minute blood vessels, averaging 0.008 mm in
diameter that connects the ends of the smallest arteries with the beginnings
of the smallest veins.70
Cell Permeability – Cellular ability to allow the passage of fluids or
substances across the cell membrane or wall.
Corticosteroids – Any of several steroid hormones secreted by the cortex
of the adrenal gland or manufactured synthetically for the use as a drug.
Drugs in this class are widely used to treat inflammatory illness such as
arthritis, asthma, and dermatitis.70
Hypodermis – Deepest layer of skin tissue composed of white, fibrous
connective tissue in which fat and elastic fibers are intermingled.34
Intracellular – Spaces within a single cell.
Ions – An atom or group of atoms that has lost one or more electrons and
has a positive charge, or has gained one or more electrons and has a
negative charge.70
Iontophoresis – An active transdermal drug delivery system that delivers
ions and charged molecules across the skin into systemic circulation at an
increase rate in a controllable manner via the use of electric current.17
Lag Time – The period of time between the application of a stimulus and
the resulting reaction.
MHz (Megahertz) – One million cycles per second or 106 hertz.70
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Micro Streaming – The flow of interstitial fluids, or the pulsating of tissue
particles associated with the a application of therapeutic ultrasound.70
Modality – The method of application or the employment of any
therapeutic agent; limited usually to physical agent and devices.
Passive Delivery Systems – A mechanism by which a drug diffuses
through the skin into the bloodstream using a simple concentration
gradient as a driving force.32
Penetration – The act of breaking or crossing a barrier.
Percutaneous – Effected though the skin; describes the application of a
medicated ointment by friction, or the removal or injection of a fluid by
needle.70
Permeation – Penetration of and spreading throughout an organ, tissue, or
space.
Phagocytosis – A three stage process by which phagocytes (neutrophils,
monocytes, and macrophages) engulf and destroy microorganisms, other
foreign antigens, and cell debris.70
Phonophoresis – The therapeutic application of ultrasound with a topical
drug in order to facilitate transdermal drug delivery.2
Piezoelectric Effect – Application of an alternating current applied to a
crystal resulting in changes of shape in tune with the electric field.45
Plasma - The liquid part of the lymph and blood consisting of serum, protein, and
chemical substances. It acts as a transport for these substances as well as position waste
products to various sites of clearance.
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Sonophoresis – The use of ultrasonic energy created by low frequency sound
waves to drive cutaneous transport of drug molecules.33
Stratum Corneum – The outer most layer of skin comprised on 10 to 20 cell
layers. It is a fairly dense tissue composed of 20% water, lipids, and other proteins.34
Transdermal Drug Delivery – A delivery system technology that enables the
passage of drug molecules across the intact skin utilizing passive and active
methods.32
Transcellular – Through, across, over, or beyond the cell.70
Unstable Cavitation – The expansion and contraction of micro-bubbles within the
cell at a rate that results in eventual explosion of the bubbles resulting in cellular
damage.24
Ultrasound – A therapeutic modality that utilizing ultrasonic energy to emit
thermal and mechanical responses within tissues.
Viable Dermis – The layer of skin located between the stratum corneum and the
dermis. Water content of this tissue is 90%.34
Viable Epidermis – The layer of skin located directly beneath the dermis and
subcutaneous tissue. It consists of a matrix of loose connective tissue comprised of
fibrous protein and an amorphous ground substance.34
Wave Frequency – A disturbance, usually orderly and predictable, observed as a
moving ridge with a definable frequency and amplitude. The number of repetitions of a
produced wave.
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Assumptions
The following assumptions will guide this study:
1.

Tissues among subjects will contain little variation in

substance and resistance to applied treatments.
2.

Tissues among subjects will respond with little variation in

response to the treatment protocol including invasive
microdialysis probe insertion.
3.

Ultrasound devices utilized in the study will perform at

desired and displayed frequencies.
4.

Subjects will be honest in reporting any medical conditions

that could affect results prior to participation.
Delimitations
The study will be delimitated to:
1.

Uninjured males and females between the ages of 18 and

30 from Brigham Young University and surroundings
counties.
2.

Individuals with no known drug allergies.

3.

Individuals with no history of adverse reactions to applied

heat therapy.
4.

Individuals with no experience of decreased extremity

sensation.
5.
injury.

Individuals with no current illness or musculoskeletal
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Chapter 2
Review of Literature

The literature review for this study is organized into the following sections:
1.

Search strategy

2.

Background and significance

3.

Transdermal drug delivery

4.

5.

6.

a.

Benefits of transdermal drug delivery

b.

Methods of transdermal drug delivery

Delivery across the skin barrier
a.

Anatomy of the skin

b.

Passive delivery systems

c.

Active (mechanical) delivery systems

Ultrasound
a.

Benefits of ultrasound: thermal effects

b.

Benefits of ultrasound: non-thermal effects

Phonophoresis
a.

7.

Sonophoresis
a.

8.

Mechanisms of phonophoresis

Mechanisms of sonophoresis

Summery

Search Strategy
PUBMed, SportsDISCUS, and CIHNAL databases were searched from using terms listed in
Table 3. Additional literature was gathered from citations in articles, course texts and symposiums.
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Background and Significance
The utilization of drug therapy in the treatment of musculoskeletal trauma is a very
common practice. These traumas are often treated with a variety of medications designed to
reduce inflammation, relieve pain, relax muscle, and a number of other desired effects. While
relief from musculoskeletal trauma can be obtained with medication, effective drug therapy is
not without its difficulties. Delivery of these drugs is administered in three ways:
1.

Oral ingestion, which can result in unpredictable levels of available drug

in the blood stream following gastrointestinal metabolism, as well as other notable side
effects such as altered liver, stomach, and kidney function following “first pass”
digestion.28-30
2.

Injection either administered intravenously or directly to the injury site,

which can be painful leading to decreased patient compliance, as well, exposure to
infection. Also, repeat injection sites often experience a prevalence of scar tissue, thus
compromising tissue integrity and possible joint and muscle function.30
3.

Topical application of medication, or transdermal delivery of drugs, which

recently has seen a rise in both clinical and research trials largely due to difficulties with
the first two mentioned modes of drug delivery.
Transdermal Drug Delivery (TDD)
Benefits of Transdermal Delivery
As recently as three years ago, 40% of all drugs in clinical trial were utilized via some
form of transdermal delivery.31 These drugs are commonly administered by topical cream,
ointment, or skin patch. Transdermal drug delivery offers major benefits over other forms of
delivery by:1,3,6,28,31,32,33,34,35,36,
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1.

Avoidance of first pass affects, producing steady state plasma
levels improving bioavailability

2.

Decreasing the dose administered as a result of liver bypass

3.

Decreasing unwanted side affects

4.

Decreasing gastrointestinal side affects

5.

Ease of discontinuance in the case of adverse reactions

6.

Increased patient compliance

Perhaps another reason accounting for the shift in research directed towards transdermal
drug delivery is financial. The development of a new drug can near $250 million and take up to
15 years to reach the market. However, exploration of varying drug delivery of existing
approved medications can be developed in half the time with 20% of the cost of new drug
development.1
Methods of Transdermal Drug Delivery
Transdermal drug delivery is a system technology that enables the passage of drug
molecules across intact skin.32, 34 Skin is the most extensively and readily accessible organ in the
body. It covers an area approximately 1.75 m2 and receives one third of circulating blood in the
body at any given time.1 The potential for utilization of skin for pharmaceutical purposes has
been recognized for many years.37 Previously the skin was thought to be impenetrable.
However, viewpoints have changed as further understanding regarding the complexity of this
organ continues to grow.
Transdermal drug delivery occurs by one of two systems. First, via passive transdermal
systems, also referred to as percutaneous absorption and second, the utilization of active
transdermal systems or a mechanical force aiding in the delivery of drugs into tissues.1,6,32
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Passive transdermal systems allow the drug to diffuse through the skin into the bloodstream
using a concentration gradient to enhance or “drive” the medication into the tissue. This
absorption can be defined as a penetration of a substance into various layers of skin and into
systemic circulation.1,32 This process occurs in three parts:
Penetration - the entry of a substance into a particular layer
Permeation - the penetration from one layer to another layer that is both
functionally and structurally different from the first layer
Absorption - the uptake of the substance into systemic circulation.

While the process of transdermal drug delivery appears to be very functional and easily available
as an alternative in drug therapy, there are complications. The primary obstacle blocking the
facilitation of this type of drug delivery is the very medium through which the process occurs:
the skin.
Delivery across the Skin Barrier
Skin Anatomy
The skin can be considered to have four distinct layers of tissue: 34
1.

Non viable epidermis (Stratum Corneum)

2.

Viable epidermis

3.

Viable dermis (corium)

4.

Subcutaneous connective tissue (hypodermis)

The stratum corneum or outer most layer of skin is the physical barrier to most
substances that come in contact with the skin.34 It is 10 to 20 cell layers, ranging from 1mm to
4mm in thickness and comprised of only 20 % water.34, 38 Most other soft tissue within the body
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is 70% water. It has been defined as a wall like structure comprised of protein bricks and a lipid
mortar.39 The stratum corneum is an effective and selective barrier to chemical permeation and
the primary adversary in transdermal drug delivery.31,40 Once through the stratum corneum,
delivered medications will diffuse more effectively between the epithelial cells, hair follicles,
and sweat glands.41
The second layer, viable dermis, is located between the stratum corneum and the dermis.
It is thicker than the stratum corneum but is comprised largely of water, and thus is far more
permeable.34 The dermis or corium is just beneath the viable dermis. It consists of a matrix of
loose connective tissue and fibrous protein.34 The hypodermis or subcutaneous connective
tissue technically is not considered a true part of the skin. It is comprised of white, fibrous
connective tissue intermingled with blood and lymph vessels. The base of hair follicles, sweat
glands, and cutaneous nerves are located in this region.34
Passive Delivery Systems
Passive transdermal permeation or “delivery” into the tissues via the skin occurs
typically in one of three ways:31,34
1.

Transcellular through the stratum corneum

2.

Intercellular permeation through the stratum corneum

3.

Transappendageal permeation via the hair follicles, sebaceous and
sweat glands

Utilization of passive transdermal drug delivery can be managed successfully in drug
therapy. The most common form of this type of delivery is seen with medicated skin patches.
While this method is used, there are concerns as to the efficacy of passive delivery. Relatively
few drugs passively penetrate the layers of the skin effectively enough to produce high

37
therapeutic levels in plasma. Difficulty also arises in delayed lag times for establishing a stable
concentration. Often it takes several hours or longer to achieve an appropriate treatment state.42
The application of this type of medication delivery can be limited and largely depends upon the
purposes for which the drug is being used. Typically this type of delivery is seen with chronic
dysfunction or ailments requiring long term medication. This prolonged treatment duration
permits increased treatment times and initial decreases of a stable concentration of circulating
medication. While it is possible to achieve a proper medicated state using passive transdermal
systems with increased times, another concern arises. Because of high levels of capillarity
located within the superficial surfaces of the skin, targeting exact tissue can be difficult with
passive delivery.
As medications are passively absorbed into the skin, the delay enables the bloodstream to
transport the slowly penetrating drug particles. If the purpose of medication is systemic, this
type of delivery can be indicated. However, effectively targeting specific tissues with
transdermal delivery can require a faster mode of delivery across the skin. In order to enhance
skin permeability it is possible to utilize the second method of transdermal drug delivery: an
active or mechanical force.
Active (Mechanical) Delivery Systems
Active or mechanical delivery systems require a physical force in which facilitation of
movement of drug molecules across the skin occurs. By using some applied force such as an
electric current or sound wave, active systems are able to deliver proteins and other large
molecules such as medications to treat musculoskeletal trauma.
The two most commonly used forms of mechanical mechanisms in transdermal drug
delivery are iontophoresis, the utilization of positively and negatively ions to deliver medication
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across the skin barrier, and phonophoresis, the utilization of ultrasound waves to alter skin
permeability allowing for increased transdermal penetration and permeation.
Ultrasound
Indications of Use
Physical agents are commonly used modalities in the treatment of musculoskeletal
injury.43 The use of ultrasound as a therapeutic modality for the treatment of musculoskeletal
trauma has been practiced for more than fifty years.23 The variety of conditions for which
ultrasound treatment is clinically indicated includes ligament sprains, muscular injury, inflamed
tendons and tendon sheaths, lacerations, excessive scar tissue, inflamed and damaged joint
capsules, bone regeneration and healing, delayed onset muscle soreness, and most recently
thrombolysis.24,44 Over the past four decades researchers of ultrasound have tried to better
explain what effect the use of this modality has upon structures within the body. While many
questions have been answered, new questions have arisen. More recently, attention has been
focused not only in tissues as a whole, but at the cellular level as well.
Benefits of Ultrasound: Thermal effects
The therapeutic benefits of ultrasound are classed in two categories: thermal and nonthermal. Ultrasound is capable of producing significant temperature changes in tissue.43 These
changes occur as the sound waves, produced by running an electric current through a synthetic
crystal of lead zarconate, cause changes of shape within the crystal. This is known as the
Piezoelectric effect.24,45 These thickness changes are transmitted to the tissue as ultrasonic
pressure waves emitting energy into the tissue.44
Experiments have reported varying levels of tissue temperature increase dependant upon
treatment time and intensity. Research done by Draper has shown as much as .6o Celsius per
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minute per watt per centimeter squared when using a 3 MHz frequency.23,25,26 These thermal
effects are often coupled with stretching, massage, and range of motion exercises all designed to
help restore normal motion and activity.
The thermal benefits alone can promote and facilitate the healing of soft tissue, but also
have been believed to be a cause of increasing transdermal drug delivery during phonophoresis.
The influx of temperature caused by therapeutic ultrasound causes an increase in blood flow as
the body aims to remain at its homeostatic state. This increased blood flow to damaged tissues
transports blood cells and phagocytes used to aid in the restoration process of healing. As blood
flow is drawn to the treatment area, the increased capillary activity enhances medicine transport
by delivering the ultrasonically driven drug into the target tissues.
For many, it is this occurrence alone for which the basis of phonophoresis is formed.
However, examination and understanding of the mechanical or non-thermal effects of therapeutic
ultrasound can further explain other increased physiologic activity that occurs during treatment.
Benefits of Ultrasound: Non-thermal Effects
Not all of the therapeutic benefits of ultrasound are related to temperature increase.
While the thermal effects and benefits of warming tissues are well documented, equally
beneficial yet often overlooked are the non-thermal or mechanical effects received during an
ultrasound treatment.23-26 When reviewing the effectiveness of ultrasound, particularly with its
role in transdermal drug delivery, it is important to examine both the thermal and non-thermal
benefits. The non-thermal or mechanical effects of ultrasound at the cellular level can be equally
beneficial in tissue healing and drug delivery. Several experiments have been successful in
isolating the non-thermal from the thermal effects of ultrasound within cellular systems.43,44,46
The most common and discussed mechanical effects are cavitation and acoustic streaming.24,46,47
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The term cavitation was first introduced by Sir John Thornycroft in the early 20th
century.47 It is defined as the formation and life of bubbles in liquids.47 It may also be referred
to as “physical forces of sound waves on micro-environmental gases within fluid.”24 During
therapeutic ultrasound treatment, sound waves travel through the coupling medium causing the
expansion and contraction of the cells.24 This event of compression and rarefaction causes
microscopic gas bubbles in the tissue fluid to expand and contract. It is believed that continuing
changes in pressure inside and around the cell can be detrimental to normal cellular function. It
is possible for cellular destruction to occur if micro-bubbles continue to expand and contract
causing “implosion”, referred to as unstable cavitation.24 While this phenomenon is not thought
to occur at therapeutic levels of ultrasound, it is believed the pulsation of gas bubbles within the
cell can not only affect cell wall permeability, but alter the function of the cell altogether. Some
hypothesize the alteration of the cell wall can render medications more effective and allow for
greater accumulation of medication to a more concentrated area.
Similar to cavitation, acoustic streaming affects the particles in and around the cell.
When an ultrasound wave is transmitted through a fluid, the momentum transfer generates a
steady motion of the fluid in the direction of the ultrasound beam flow .46 This force created by
the sound wave is capable of displacing ions and other small molecules.48 Acoustic streaming
can be divided into two areas: bulk streaming and micro-streaming. Bulk streaming occurs when
an ultrasound beam propagates in a liquid and there is movement of the fluid in a single
direction.49 This event is less powerful than micro-streaming. Micro-streaming forms as
“eddies” adjacent to the source of movement.50
Studies viewing the effects of acoustic streaming and cavitation on cells showed growth
retardation of cells in vitro, increased protein synthesis51,52, and membrane alterations.53,54 This
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would suggest that ultrasound can first injure the cell, retarding growth, and then initiates a
healing response with increase protein production.24 The original thought that ultrasound was a
heating modality and thus only to be used in the later stages of tissue healing and regeneration is
no longer the case. Performing therapeutic ultrasound in the acute stages of injury renders it
possible to assist in the early stages of regeneration and repair. The application of ultrasound to
areas marred by swelling can increase protein production and assists in tissues “stuck” within the
inflammatory process.
It has previously been stated that ultrasound has two therapeutic effects, thermal and nonthermal. It has also been postulated that both of these affects can assist in healing and tissue
repair. Now that both have been reviewed, it is important to discuss the interaction between the
two. Is it possible to obtain the mechanical effects of ultrasound without exposing tissue to the
thermal or heating affects? Research has indicated that sound waves traveling through a medium
can cause an expansion and contraction of the cell. These effects can alter cell wall permeability
and cell function.24
The extent to which this phenomenon occurs depends upon the frequency and intensity of
the sound waves. Typically, therapeutic levels of ultrasound range from 1 to 3 MHz at
frequencies around 1-2 W/cm2. Depending upon desired heating levels treatment times may
vary. By lowering the frequency of the sound wave, you will experience increased cavitation
and potential micro-explosions of cells or unstable cavitation. As previously stated, typical
therapeutic levels of ultrasound are performed at higher frequencies allowing for the benefits of
acoustic streaming and cavitation without the detriments of excessive oscillation.
By lowering the intensity of the sound wave it is possible to obtain the mechanical
benefits of ultrasound without increasing temperature.24 Lower frequencies may also allow for

42
increased non-thermal effects without tissue heating. Previous beliefs that therapeutic ultrasound
in the acute stage of injury is detrimental can be dispelled if proper treatment parameters are
followed. Increased protein synthesis and cellular activity can be enhanced without tissues being
exposed to vascular thermal reactions.
The practice of ultrasound remains a widely used modality for therapists in clinics,
hospitals, and training rooms. The thermal effects promote increased healing of tissue and
muscular relaxation, preparing the area for various treatments used to restore normal motion.
Equally beneficial and more recently understood are the mechanical benefits of this modality. It
is through these mechanical effects that the process of phonophoresis occurs.
Phonophoresis
Mechanism of Phonophoresis
Phonophoresis is the process by which ultrasound waves emitted during treatment push
topically applied medication, mixed with conductive ultrasound gel, into the body.2,45,55 This
permeation and absorption across the stratum corneum and into the tissue is believed to occur as
a result of the previously discussed mechanical effects of ultrasound. The utilization of
ultrasound waves to enhance drug delivery is not a new concept. Studies reporting percutaneous
absorption of medicine began in the 1950’s by Fellinger and Schmid.56 As a method of
transdermal drug delivery, it too is believed to have advantages over traditional drug therapy.
Phonophoresis is non-invasive and does not expose patients to painful injections or increased
risk for infection. The application of the medication directly over the treatment site eliminates
problems with oral ingestion such as gastric irritation and lessons the metabolic elimination by
avoiding the liver.2,17,57,58 Indications for phonophoresis use include injuries where traditional
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medications would also be suggested such as muscle soreness, inflammation, bursitis, and
tendonitis.2,4
Effectiveness of Phonophoresis
As with the general discussion regarding transdermal drug delivery, complication and
doubts do arise as to the efficacy of phonophoresis. Numerous studies have been conducted
assessing the clinical effectiveness of phonophoresis.6-11 However, part of the difficulty in
verifying the effectiveness of this technique stems from varying methods of evaluating the drug
delivery. A majority of research conducted involving human subjects has relied heavily upon
patient reported decreases in pain and dysfunction rather than direct tissue analysis.18,19,59,60
Other in vivo studies reporting decreasing symptoms following treatment had uncontrolled
variables such as varying patient treatments administered in conjunction with the phonophoresis
treatments.19 While many therapists do attest to its benefits, approximately 75% of reviewed
research articles indicate some level of effectiveness, uncertainty with treatment parameters and
delivery mediums continues to persist.5,3,18,59,61,62
As researchers continued to attempt to understand these parameters and how ultrasound
waves can enhance transdermal delivery, focus was directed at the non-thermal or mechanical
affects occurring during ultrasound treatments. Initially delivery and absorption was thought to
be as result of increased thermal effects occurring during ultrasound. However, as studies began
to examine this occurrence, the mechanical affects appeared to play the primary role in the drug
delivery.13,14 For example, in a study by Merino et al. ultrasound was delivered at 20 KHz at 15
W/cm2 resulting in a 20oC rise in temperature that resulted in a 35-fold increase in the level of
delivered drug across porcine skin in vitro. However, when the same tissue was heated utilizing
another form other than ultrasound to produce a thermal effect, the permeability of the drug

44
increased only 25 percent.14 The decreased increase can be explained by the previously discussed
methods of passive transdermal delivery such as absorption into sebaceous glands and hair
follicles. But the increased levels of delivered medicine following ultrasound treatments is
attributed to alteration within the stratum corneum as a result of delivered sound waves affecting
cellular permeability.
While studies such as this and others performed have resulted in the general acceptance
of phonophoresis as an effective active drug delivery method, questions continue to be asked. If
the mechanical forces of sound waves on tissues within the stratum corneum and other dermal
layers can be affect cellular permeability, can altering ultrasound treatment parameters result in
increased transdermal drug delivery effectiveness?
Sonophoresis
Mechanism of Sonophoresis
Typical phonophoresis treatments occur within the range of 1 to 3 MHz. The growing
understanding and acceptance of mechanical forces produced by ultrasound on cells such as
cavitation and acoustic streaming help explain the mechanism of phonophoresis. However, this
knowledge has led to the idea of further altering parameters with this type of active delivery to
enhance transdermal delivery. By lowering the frequency of the sound waves it is hypothesized
that the mechanical effects of the sound waves on cells will be enhanced. Low frequency
ultrasound (20 - 500 KHz), or sonophoresis, is shown to be significantly more potent in
enhancing skin permeability compared to the traditionally used frequencies of 1 and 3 MHz.65
This is a direct result of the increased acoustic cavitation occurring in lower ultrasound
frequencies. The number and size of cavitation bubbles appears to be inversely correlated with
the ultrasound application frequency.66 Mitragotri et al. demonstrated increased permeability of
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skin tissue utilizing frequencies of 20 KHz with drugs used to enhance immune response.28,67
Further studies by Mitragotri utilizing frequencies of 20 – 40 KHz have shown to increase the
skin’s permeability to insulin by 400 times.68
Low frequency ultrasound waves facilitate a considerable amount of cavitation as they
pass through the tissue medium.33 This ultrasonically produced formation of cavities promotes
perturbation within the stratum corneum. The result is increased channels within the lipid
structures, thus altering permeability of the stratum corneum to drug molecules.69 This altered
state results in increased penetration, permeation, and absorption of medication into the target
tissues. Studies suggests that sonophoresis can enhance transport rates of molecules across the
skin 100 fold.63
At this time the majority of research done to evaluate the utilization of sonophoresis as
an active system in transdermal drug delivery has largely been devoted to insulin and other drugs
used to enhance the immune system. The fact the many therapist currently utilize traditional
frequencies of ultrasound or phonophoresis in the treatment of musculoskeletal trauma leads
towards the need for continued exploration of sonophoresis as a more effective active
transdermal drug delivery system.3,35,36
Summery
Transdermal drug delivery has become an important and often utilized means of drug
administration.29 The benefits of transdermal drug delivery over traditional methods of drug
therapy are numerous:1-6,12,31-33
-avoidance of first pass metabolism
-ability to discontinue administration of drug by cessation of treatment
-control drug delivery for a longer time
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-avoid gastrointestinal transit of drug component
-decrease need for injections
-less exposure to infection or drug reaction
-improved patient compliance
As the costs of drug production and lengthy process of drug approval continue to increase, new
mediums for more effective delivery should continue to be examined. While the utilization of
passive mediums for drug delivery such as topical ointments and skin patches continues to be
prescribed, further research in areas of active delivery should be explored.
Traditional delivery methods of iontophoresis and phonophoresis continue to be
recognized as effective mediums. However, as the mechanical properties of sound waves
emitted via ultrasound devices continues to be understood, further evaluation is necessary. Not
only to enhance understanding of non-thermal ultrasound effects, but also to increase utilization
of those effects in more effectively aiding in the transmission, permeation, and absorption of
drugs into target tissues. While current research in sonophoresis has largely been devoted
towards drugs designed to facilitate general health, advancement into the treatment of
musculoskeletal trauma can provide patients with safer and more effective drug therapy
alternatives.
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Chapter 3
Methods
Design
A 2 X 2 X 3 factorial will be used. The first factor is the medicine that will be utilized
during the study. The second factor is the intensity of ultrasound (1 MHz, 45 KHz, and sham).
Subjects will receive one treatment from an assigned treatment group. Treatment protocol will
consist of 10 minute sessions. Dependant variables will be recorded and consist of levels of
medication collected during ultrasound delivery.
Subjects
Thirty one healthy individuals will be recruited as subjects (10 subjects per treatment
group). Prior to inclusion each subject will complete an information and health and history
questionnaire. Subjects with recent or current history of general illness or history of decreased
sensation to upper extremities will be excluded. Skin fold measurements at the probe insertion
site located at the proximal extensor group of the elbow will be taken to evaluate adipose levels.
Subjects with measurements greater than 10 mm thickness will be excluded. The institutional
review board will approve this study and the subjects will give informed consent(Appendix A).
Subjects will be assigned to a treatment group based upon random draw.

Equipment
Skin Fold Calipers
Ultrasound Devices and Coupling Gel. 1 MHz ultrasound and sham ultrasound will
be performed using a (Accelerated Care Plus, Reno, NV). 500 KHz and 20 KHz ultrasound will
be performed using ultrasound transducers produced by the Brigham Young University Chemical
Engineering Department(Provo, UT). Aquasonic 100 water soluble hypoallergenic ultrasound
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transmission gel (Parker Laboratories, Inc, Fairfield, NJ) will be mixed with a topical cortisone
gel.
Intradermal microdialysis
Probe construction: All components of the intradermal microdialysis probe are inert
and non-reactive with human tissue. A 37 cm length of spring tempered stainless steel wire
(0.002 inch diameter, Alan Baird Ind., NJ) is used to support the probe during construction and
insertion into the tissue. The microdialysis probe consists of an 8 cm piece of polyimide tubing, 4
cm of hollow fiber dialysis tubing, 4 cm of polyimide tubing, 20 cm of PE 10 tubing, and 6 cm of
PE 50 tubing. The polyimide tubing (0.0064 inch OD, Cole-Parmer, IL) is inserted 1 cm into the
hollow fiber tubing and welded with cyanoacrylate glue on each end leaving 2 cm of exposed
membrane. All welds are verified under a dissecting microscope. The hollow fiber microdialysis
membrane is a regenerate cellulose membrane with an approximate 13,000 Dalton molecular
weight cut-off (0D = 220 µm, Spectrum Laboratory, TX). After completion the probe is checked
to see if it fits inside a 27 gauge needle. Probes are packaged individually and gas sterilized. The
hollow fiber membrane allows equilibration of the perfusate solution with the interstitial fluid in
the skin. Drug delivery analysis will be performed by Measurement of Cortisol (hydrocortisone)
assay – Enzyme immunoassay (Immuno Biological Laboratories, Hamburg, Germany). 96 well
microtiter plate. Measurement of Cortisol (hydrocortisone) assay – Enzyme immunoassay
(Immuno Biological Laboratories, Hamburg, Germany). 96 well microtiter plate.
Procedures
Subjects will report to the Brigham Young University Human Performance Research
Center for all screening and testing. Three skin fold measurements will be taken at the treatment site

located at the proximal extensor group of the elbow with an average of the three measurements used
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to determine subject inclusion. Qualified subjects will randomly draw to determine treatment group.
Treatment groups consist of:

Group One: 1 MHz 1.0 w/cm2 – Treatment duration: 10 minutes
Group Two: Sham Ultrasound – Treatment duration: 10 minutes
Group Three: 45 KHZ – Treatment duration: 10 minutes
Probe placement: Probes will be placed under aseptic conditions into the medial
gastrocnemius muscle approximately 2 inches superior to the musculotendinous junction of the
Achilles tendon with a 27-gauge needle used as a guide cannula.
A second probe will be inserted at a control site located on the approximate location on
the opposite limb. Both probe entrance and exit sites on the skin will be separated by at least 6.0
centimeters. The guide cannula will be inserted horizontally in the dermis through the muscle.
Probe depth and muscle penetration, as well as adipose and skin thickness will be verified and
recorded with Doppler ultrasound imaging. After confirming that the needle has penetrated the
muscle, the microdialysis probe will be fed through the guide cannula. Following insertion of
the probe the needle will be removed with the probe left in place.
After placement, the probes will be perfused with 0.9% sterile saline at a rate of
10µl/min with a Harvard infusion pump for 70 minutes. The purpose of this period is to allow
tissue to recover from needle and probe insertion. After insertion, the volume of dialysate (fluid
coming out of the probe) will be monitored for five minutes. If this volume is significantly lower
than expected (indicating a leak) the probe will be replaced. At minute 70 of the recovery period
we will alter the infusion rate to 5µl/min and dialysate will be collected for 20 minutes to
determine pre-treatment tissue cortisol levels. The perfusion rate will remain constant for the
remainder of the treatment.
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Drug Delivery Treatment. After 20 minutes of collecting dialysate at 5µl/min, the vials
will be replaced. We will then place the prepared medicated ultrasound coupling gel on a
treatment area 2 times the size of the ultrasound head.
We will use a pre fabricated template to isolate the treatment area and ensure consistent
treatment size. The ultrasound operator will guide the sound head for the duration of the 10minute treatment at a rate of approximately 4 cm per second. During the treatment, dialysate
from the intramuscular microdialysis probe will be collected for analysis.
Following the treatment, subjects will remain in the prone position for an additional 10
minutes while dialysate continues to be collected at a rate of 5µl/min in an effort to ensure that
medication delivered during the ultrasound treatment will pass to the vials. After 10 minutes the
saline perfusion will be terminated and the collected fluid will be stored in the laboratory freezer.
We will remove the ultrasound template and clean medicated ultrasound gel from the dermis.
We will remove the intramuscular microdialysis probes without discomfort and portal sites
within the tissue will be treated with triple antibiotic and covered with a band aid. We will give
subjects a basic wound care guide with contact information should any questions arise.
Statistical Analysis
We will use a 2 X 2 X 3 (condition x time x treatment) ANCOVA to analyze change in
cortisol levels in samples collected before and after treatment in both treatment sites and control
sites. Bonferroni post hoc multiple comparison test will be used to examine individual
differences in cortisol levels between the 3 treatments. For all differences, the level of
significance will be set at P < .05. Data will be analyzed using MINITAB software.
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Table B 2. Research Questions and Statistical Analysis Procedures Performed_________
1. Is ultrasonic frequency a significant parameter in enhancing the delivery of cortisone
(using 10% hydrocortisone cream)?
a. I used a General Linear Model with ANCOVA and repeated measures to determine if
a group difference existed and to see what covariates used in analysis were
significant:
i. In SPSS
1. Analysis Variance – Repeated Measures Model
2. Covariates were: Muscle Depth Treatment (MDTx), Probe Depth
Treatment (PDTx), Pre-Cortisol Treatment (PreCTx), Muscle Depth
Control (MDC), Probe Depth Control (PDC), Pre-Cortisol Control
(PreCC)
3. Response Variable was: change
4. Factor Variable was: sham, 45 KHz, 1 MHz
2 X 3 Analysis of Variance Table____________________________________________
Source
Sum of
Mean
Prob
Term
DF
Squares
Square
F-Ratio
Level ______
Cortchange
1
16.531
16.531
.904
.352
Cortchange*MDTx 1
117.807
117.807
6.443
.019
Cortchange*PDTx
1
14.320
14.320
.783
.386
Cortchange*PreCTx 1
19.446
19.446
1.064
.314
Cortchange*MDC
1
24.372
24.372
1.333
.261
Cortchange*PDC
1
74.884
74.884
4.096
.055
Cortchange*PreCC 1
184.413
184.413
10.086
.004
Cortchange*Group 2
12.390
6.195
.339
.716
Error(Cortisolchange) 22
402.245
18.284 ______________________________
There was no difference in change between the control and treatment limb (F1,22 = .9,
P = .352). There was also no difference in change between any of the three treatment groups
(F2,22 = .34, P = .716). Since there was no indication of difference between treatments or groups,
no further analysis or statistical tests were performed.

2. Do pre-treatment cortisol levels, depth to the treated muscle, and depth of the
microdialysis collection probes influence the analysis determining if drug delivery
occurred?
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The following measured covariates were significant, appearing to influence the post cortisol
levels in the collected dialysate: Muscle Depth (F1,22 = 6.4, P = .019), Probe Depth (F1,22 = 4.1, P
= .055), and Pre Cortisol Level (F1,22 = 10.1, P = .004). Despite the fact that these covariates
were significant on either the treatment or control, we should still continue to measure and
control at both the treatment and control sites
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Table B 3. Subject Information and Data Collection Form_________________________

Subject Information Form

Date:
Subject Number _______
Treatment Group_______
Number in Group_______
Ultrasound Imaging Data
Treatment Site
Depth to Muscle _______
Probe Depth
_______
Control Site
Depth to Muscle _______
Probe Depth
_______

Note any requested variations on treatment protocol:
(Excessive movement, discomfort, pain, etc)
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Figure B 1. Institutional Review Board Application______________________________

Application for the Use of Human Subjects

Application

Information
1. The Effects of Low Frequency Ultrasound in Transdermal Drug Delivery
2. Principal Investigator: Aaron Wells

3. Contact Person:
(if different from PI):
Title:

Title: ATC,L PhD
Dept: Exercise Science
Dept:
Student
1861 W 870 N
Address (+ Zip):
Pleasant Grove, UT 84062
Phone: (801) 796Email: Wells@byu.edu Phone:
Email:
6758
4. Co-Investigator(s): David Draper
(Name & Affiliation) Professor – Brigham Young University
5. Research Originated By: (Check One)
~ Faculty
X Student
~ Staff
6. Research Purpose:
~ Grant
X Dissertation
~ Thesis
~ ORCA
Scholarship
(Check All that Apply) ~ Other
~ Honors Thesis ~ Course Project: Which Course?
7. Correspondence Request:
~ Mail
X Call for Pick-Up

Research Study Synopsis
1. Short Study Description: Therapeutic drug use can have undesirable side affects, whether it is
possible organ and tissue damage due to oral medication or pain, infection, and scarring with
injection. Questions also arise as to the efficacy of drug delivery to target tissues as well as other
systemic affects with prolonged drug use. The use of ultrasound in conjunction with transdermal
drug delivery is common. However there are doubts about its success in delivering medication
to the desired treatment areas. The purpose of this study is to see if altering the frequencies of
therapeutic ultrasound increases transdermal drug delivery.
Study Length
What is the duration of the study? The study will take approximately 75 days to complete
Location of Research
a. Where will the research take place? Data collection will take place in the Health and Human
Performance Modality Laboratory in 126 RB
b. Will the PI be conducting and/or supervising research activity at any sites not under
the
jurisdiction of the IRB? No
4. Subject Information:
a. Number of Subjects: 30
b. Gender of Subjects: Male and Female
c. Ages – Varies
5. Potentially Vulnerable Populations: (Check All that Apply)
~ Children
~ Pregnant Women
~ Cognitively Impaired
~ Prisoners
Institutionalized X Faculty’s Own Students
~ Other. Please describe:

~
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6. Non-English Speaking Subjects
a. Will subjects who do not understand English participate in the research: ~ Yes
X No
b. If yes, describe your resources to communicate with the subjects:
c. Into what language(s) will the consent form be translated:
7. Additional Subject Concerns
a. Are there cultural attitudes/beliefs that may affect subjects in this study?
~ Yes
X
No
b. If yes, please describe attitudes and how they may affect subjects.
8. Dissemination of Research Findings
a. Will the research be published? X Yes
~ No
If yes, where if known?
b. Will the research be presented? X Yes
~ No
If yes, where if known?
9. External Funding
a. Are you seeking external funding? ~ Yes
X No
What agency?
b. Have you received funding? X Yes
~ No
c. Dollar amount? $3000
10. Method of Recruitment: (Check All that Apply)
X Flyer X Classroom Announcement
~ Letter to Subjects
~ Third Party
~
Random ~ Other
11. Payment to Subjects
a. Will subjects be compensated for participation? X Yes
~ No
If yes, please indicate
amount: $30
b. Form of Payment: X Cash ~ Check
~ Gift Certificate ~ Voucher
~ 1099 ~
Other
c. Will Payment be prorated? ~ Yes X No If yes, please explain:
d. When will the subject be paid? X Each Visit
~ Study Completion
~ Other
12. Extra Credit
a. Will subjects be offered extra credit? ~ Yes X No
b. If yes, describe the alternative:
13. Risks: Identify all potential risks/discomforts to subjects. The insertion of the
microdialysis probe may cause small discomfort. The application of therapeutic ultrasound
may produce mild warmth.
14. Benefits:
a. Are there direct benefits to participants? ~ Yes X No If yes, please list.
b. Are there potential benefits to society? X Yes ~ No If yes, please list. The utilization
of alternate routes of drug delivery can increase patient compliance, reduce drug costs, and
increase safer delivery of medication to tissues.
15. Study Procedures:
a. What will be the duration of the subjects’ participation? A one time two hour visit
b. Will the subjects be followed after their participation ends? ~ Yes X No If yes,
please describe.
c. Describe the number, duration and nature of visits/encounters. Students will arrive at the
laboratory and fill out informed consent. Subjects will then have adipose tissue thickness
measured to ensure qualification. They will then have the microdialysis probe inserted and
undergo a 90 minute recovery time. Treatment application lasting 10 minutes will be
performed. Subjects will then have probe removed and insertion site will be cleansed and

66
covered. Subjects will be given a wound care sheet with emergency contact information
and paid for their participation. They will then be excused.
d. Is the study X Therapeutic? ~ Non-therapeutic?
e. List all procedures that will be performed to generate data for the research.
Subjects will report to the Brigham Young University Human Performance Research
Center for screening and testing. Skin fold measures will be taken at the treatment site
located at the proximal wrist extensor group. The average of three measurements will be
used to determine insertion site and depth needed to ensure penetration of the muscle.
Subjects will randomly draw to determine treatment group. Treatment groups consist of:
Group One: Sham Ultrasound– Treatment duration: 10 minutes
Group Two: 45 KHz .056 w/cm2 – Treatment duration: 10 minutes
Group Three: 1 MHz 1.0 w/cm2 50% Duty Cycle – Treatment duration: 10 minutes
Probe Placement. Under sterile conditions the probe is placed in the medial
gastrocnemius muscle distal to the knee at a depth no less than 1 cm into the muscle with a 27gauge needle used as a guide cannula. A second probe will be inserted at a control site located in
the gastrocnemius muscle of the opposite leg in the approximate location of the treatment site.
The entrance and exit sites on the skin are separated by at least 2.5 cm. The guide cannula is
inserted horizontally in the dermis and the microdialysis probe is fed through the guide cannula.
The needle is removed with the probe left in place. Measurements of tissue to estimate adipose
and muscle depth are performed with skin fold calipers. Probe depth and muscle penetration will
be verified utilizing ultrasound imaging following insertion. After placement, the probes are
perfused with 0.9% saline at a rate of 10 µl/min with a Harvard infusion pump. A 90 minute
recovery period after probe insertion and associated soft tissue trauma is required to allow local
skin blood flow to return to baseline, as well as ensure normal Cortisol levels present in the
muscle before data measurements can be made.
Placement of the microdialysis probes into the muscle may produce some transient pain
or discomfort. Risks associated with insertion of the microdialysis probe include infection and
irritation in the skin but these are reduced by observance of proper sterile techniques. The
microdialysis probes will be sterilized using clinically employed
techniques at the Human Performance Research Center (gas sterilization).
The microdialysis probe is placed in the muscle using a guide cannula (a 27-gauge needle
under the skin). As such, the risk of damaging the probe and incurring a leak or break is
minimized. After insertion we perfuse each probe with sterile saline at 5 µl/min and monitor the
volume of dialysate (fluid coming out of the probe) for five minutes. If this volume is
significantly lower than expected (indicating a leak) the probe is replaced.
Drug Delivery Treatment
Following probe insertion and 90 minute recovery period, the prepared medicated
ultrasound coupling gel will be placed on a treatment area 2 times the size of the ultrasound head
utilized for the specific treatment. A pre-fabricated template will be used to isolate the treatment
area and ensure appropriate treatment area and size. The ultrasound operator will guide the
sound head for the duration of the 10 minute treatment at a rate of approximately 4 cm per
second, advising the subject to immediately report any unexpected discomfort during the session.
During the treatment, perfusate from the intramuscular microdialysis probe will be collected into
test tubes for analysis. At the conclusion of the treatment, subjects will remain in the prone
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position for an additional 10 minutes to permit dialysate collection. Following that period, the
subject will have the ultrasound template removed and medicated ultrasound gel cleansed from
the dermis. Intramuscular microdialysis probes will be removed without discomfort and portal
sites within the tissue will be treated with triple antibiotic and covered with a band aid. Subjects
will then be given a basic wound care guide with contact information should any questions arise.
Subjects will then be given a $35 honorarium for participation and excused.
16. Informed Consent:
a. Are you requesting Waiver or Alteration of Informed Consent? ~ Yes X No If yes,
please fill out the waiver of informed consent and attach it.
b. Briefly describe your process to obtain consent: An informed consent form describing
testing purpose, procedures, and possible risks will be distributed to subjects upon arrival to
the laboratory. Subjects will be given time to read the informed consent form and be asked
if they have any questions. They will then be asked to sign the consent.
17. Confidentiality:
a. Are the subject’s social security number, BYU ID number or any identifier (other
than study number and
initials) being sent off site? ~ Yes X No If yes, describe and explain reasons.
b. Will any entity other than the investigative staff have access to medical, health or
psychological information
about the subject? ~ Yes X No If yes, please indicate who.
c. Briefly describe provisions made to maintain confidentiality of data, including who will
have access to raw data, what will be done with the tapes, etc. All records and data will be
kept by the principle investigator under lock in the office of the principle investigator. All
records kept on computer of the principle investigator will be password protected.
d. Will raw data be made available to anyone other than the PI and immediate study
personnel? ~ Yes X No
If yes, describe the procedure for sharing data. Include with whom it will be shared, how
and why.

Part C
The attached investigation involves the use of human subjects. I understand the university’s
policy concerning research involving human subjects and I agree:
1. To obtain voluntary and informed consent of subjects who are to participate in this project.
2. To report to the IRB any unanticipated effects on subjects which become apparent during
the course of, or as a result of, the experimentation and the actions taken.
3. To cooperate with members of the committee charged with continuing review of this
project.
4. To obtain prior approval from the committee before amending or altering the scope of the
project or implementing changes in the approved consent document.
5. To maintain the documentation of consent forms and progress reports as required by
institutional policy.
6. To safeguard the confidentiality of research subjects and the data collected when the
approved level of research requires it.
Signature* of the Principal Investigator:

Date:
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Figure B 2. Institutional Review Board Approval Letter___________________________
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Figure B 3. Institutional Review Board Consent to be a Research Subject ____________
The Effects of Low Frequency Ultrasound in Transdermal Drug Delivery
Informed Consent to Be a Research Subject
1. Description and purpose of the research study
The purpose of this research study is to evaluate the efficacy of transdermal drug delivery
when varying the frequency of the ultrasound during phonophoresis. Therapeutic ultrasound is
an FDA approved treatment. The practice of combining topical medication with ultrasound gel
to deliver medication to tissues is common in therapeutic settings.
Aaron M. Wells, MS, ATC,L is conducting this research study, and he is assisted by Dr.
David O. Draper, EdD, ATC,L. Aaron Wells is a certified Athletic Trainer and Doctoral
Candidate at Brigham Young University. Dr. Draper is a certified Athletic Trainer and professor
of Athletic Training at Brigham Young University.
You have volunteered to participate on your own free will.
You possess a lean Gastrocnemius muscle.
2. Exclusion Criteria
Females currently menstruating are asked not to participate. Individuals with calf bruise,
infection, open wound, rash, swelling, decreased circulation in the area to be treated, deficits in sensation
in the area to be treated, presence of a pacemaker, malignancy, needle phobia, or injury to either lower
extremity within the past 2 weeks should not participate in this study.

3. Procedure
If you choose to participate in this research study on transdermal drug delivery you will
be asked to make a visit to the Therapeutic Modalities (RM 123) in the Richards Building at
BYU. Prior to beginning the treatment a 5 cm area of both the left and right gastrocnemius
muscle will be cleansed with an antibacterial agent (betadine). Two small sterile microdialysis
probes will be inserted no greater than 2 cm into each gastrocnemius muscle located proximal to
the musculotendinous junction of the achillis tendon. A 90 minute recovery period will be used
to allow the body to adjust to the insertion of the probes prior to the application of treatment.
You may feel gentle warmth during the ultrasound treatment. The microdialysis probes will
collect interstitial fluid during application of the treatment. The total anticipated time at the
Therapeutic Modality Laboratory will be 150 minutes.
4. Risks/Discomforts
Risks
As with the introduction of any instrument through the skin barrier there is a small
chance of infection related to participation in this study. However, these research methods have
need used with several subjects with 0% incidence of infection.

70
Discomforts
The introduction of the small microdialysis probe into the gastrocnemius muscle will
create a discomfort similar to that of having blood drawn during a laboratory test. During the
treatment it is possible that you may feel gentle warmth in the arm. However, the treatment at no
time should produce a burning sensation or any pain or discomfort. In the unusual instance that
pain or discomfort does arise you should immediately inform the researcher and the treatment
will be altered or terminated.
5. Benefits
There are no known health benefits to you, the subject, in participating in this study.
However, this research will help health care professionals to understand optional methods of
drug delivery as well as further identify non-thermal affects of ultrasound use.
6. Confidentiality
Participation in this research study is voluntary. You have the right to withdraw form this
study at anytime, including after supplying informed consent. Withdrawing from this study will
not affect your grades or standing as a BYU student or employee. Strict confidentiality
regarding your identity and participation in this study will be maintained. No individual
identifying information will be disclosed. You will be assigned a subject number and at no time
will your name be disclosed during the study or in any manuscripts that may be published from
the study.
7. Researchers names/ phone numbers/ address
Should you have any questions regarding participation in this study please contact:
Aaron Wells
Brigham Young University
267 Smith Field House
Provo, UT 84602
(801) 422-8674
8. Information regarding the rights of the research participants
If you would like additional information on you rights as a research participant in this
research project you may contact the Institutional Review Board at Brigham Young University.
9. Signature
I have read, understood, and received a copy of the above consent and desire of my own
free will to participate in this study and accept the risks relating to this study.
_________________________________
Research Subject’s Name (please print)
_________________________________
Research Subject’s Signature

_________________
Date
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Figure B 4. Subject Setup Position___________________________________________
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Figure B 5. Doppler Ultrasound Image of Microdialysis Probe_____________________
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Appendix C
Additional Results
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Table C 2. Sham Group Individual Measurements.
______________________________________________________________________________________

Subject Pre Cortisol Post Cortisol
Change* Muscle Depth Probe Depth
(ng/ml)
(ng/ml)
(ng/ml)
(cm)
(cm)
________________________________________________________________________
Control Limb
1
11.9
29.9
18.1
0.34
1.37
2
12.9
11.9
-0.2
0.44
1.04
3
11.3
11.9
0.5
0.25
0.90
4
23.7
19.2
-4.5
0.27
1.23
5
14.1
15.9
1.8
0.30
1.11
6
11.6
16.6
4.9
0.20
1.28
7
12.3
13.2
0.9
0.24
1.34
8
10.4
13.4
3.0
0.23
1.01
9
20.3
15.4
-4.8
0.19
0.80
10
14.2
11.0
-3.2
0.23
1.22
Average
14.2
15.8
1.7
0.27
1.13
Treatment Limb
1
13.2
2
11.7
3
15.9
4
18.1
5
16.4
6
13.9
7
15.1
8
12.9
9
16.5
10
28.2
Average
16.2

10.4
12.1
34.7
18.7
16.7
14.9
18.3
17.3
13.6
17.1
17.3

-2.8
0.4
18.7
0.6
0.3
0.3
3.2
4.3
-2.9
-11.1
1.1

0.41
0.49
0.15
0.30
0.35
0.22
0.21
0.22
0.23
0.25
0.28

1.03
1.59
1.13
1.46
1.79
1.63
1.50
1.22
1.15
1.29
1.38

*Change is the difference between pre-treatment cortisol and post treatment cortisol
measurement
________________________________________________________________________
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Table C 3. 45 KHz Group Individual Measurements.
________________________________________________________________________
Subject Pre Cortisol Post Cortisol
Change* Muscle Depth Probe Depth
(ng/ml)
(ng/ml)
(ng/ml)
(cm)
(cm)
________________________________________________________________________Contr
ol Limb
1
18.9
20.3
1.3
0.26
1.45
2
19.7
17.4
-2.3
0.27
1.15
3
14.1
13.0
-1.0
0.24
1.18
4
17.3
12.5
-4.8
0.31
0.78
5
19.9
20.0
0.2
0.25
1.65
6
11.6
12.6
0.9
0.34
1.17
7
15.5
13.4
-2.2
0.25
1.09
8
12.4
14.6
2.2
0.26
1.28
9
14.5
12.0
-2.5
0.29
1.79
10
20.2
16.8
-3.3
0.25
1.27
11
18.5
16.1
-2.4
0.22
1.18
Average
16.6
15.3
-1.3
0.27
1.27
Treatment Limb
1
18.9
2
16.4
3
14.8
4
12.2
5
20.6
6
11.8
7
15.4
8
13.5
9
15.9
10
18.9
11
18.1
Average
16.1

20.0
18.9
13.8
11.8
24.4
12.8
15.3
14.9
16.1
22.0
19.1
17.2

1.2
2.6
-1.0
-0.5
3.8
0.9
-0.1
1.4
0.8
3.1
1.0
1.1

0.29
0.26
0.27
0.32
0.29
0.32
0.23
0.26
0.28
0.19
0.24
0.27

1.23
1.08
1.57
1.44
1.68
1.60
1.17
1.17
0.90
0.90
1.05
1.25

* Change is the difference between pre-treatment cortisol and post treatment cortisol
measurement
________________________________________________________________________
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Table C 4. 1 MHZ Group Individual Measurements.
________________________________________________________________________
Subject Pre Cortisol Post Cortisol
Change* Muscle Depth Probe Depth
(ng/ml)
(ng/ml)
(ng/ml)
(cm)
(cm)
________________________________________________________________________
Control Limb
1
21.3
11.6
-9.78
0.17
1.01
2
10.1
26.0
15.9
0.31
1.20
3
13.8
20.7
6.9
0.29
1.70
4
12.1
13.6
1.6
0.26
1.31
5
13.3
16.8
3.5
0.24
1.14
6
14.8
13.8
-0.9
0.29
1.16
7
14.5
12.4
-2.1
0.27
1.00
8
17.6
17.9
0.4
0.31
1.32
9
13.8
15.1
1.3
0.28
1.66
10
34.7
21.1
-13.1
0.29
1.40
Average
16.5
16.9
.4
0.27
1.29
Treatment Limb
1
16.8
2
14.1
3
15.7
4
14.3
5
12.4
6
15.6
7
12.8
8
21.1
9
14.2
10
21.5
Average
15.9

30.1
35.4
16.1
17.2
19.4
14.2
11.6
16.5
14.7
24.1
19.9

3.3
1.3
.4
.9
.9
1.4
1.3
4.6
.5
.6
.1

0.22
0.30
0.23
0.28
0.24
0.27
0.30
0.30
0.25
0.29
0.27

1.14
1.31
1.25
1.65
1.22
1.20
1.54
1.28
1.34
1.32
1.33

* Change is the difference between pre-treatment cortisol and post treatment cortisol
measurement
_____________________________________________________________________
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Table C 5. Change* in Dialysate Cortisol Levels (ng/ml); Mean ± SD and Range
________________________________________________________________________
Sham
5 KHz
MHz
________________________________________________________________________
Control
1.7 ± 6.6
1.3 ± 2.2
.4 ± 8.1
Treated
1.1 ± 7.5
1.1 ± 1.5
.1 ± 7.8
Range
Control
Treated

18.1 – -4.9
18.7 – -11.1

0.2– -4.8
0.8– -0.5

5.9 – -13.1
21.3 – -4.6

* Change is the difference between pre-treatment cortisol and post treatment cortisol
measurement
________________________________________________________________________
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Figure 1. Treatment and Control Dialysate Cortisol Levels (ng/ml)
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Appendix D
Recommendations for Future Research
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Recommendations for Future Research to Extend the Results of this Dissertation

1. Conduct testing at the same time each day with all subjects to help control for variation in
cortisol levels. Cortisol levels vary throughout the day.
2. Conduct testing in the morning, no more than 3 hours after being awake and no less than
1 hour from sleep. Control activity level by restricting exercise prior to testing. Cortisol
levels are generally higher in the morning and fluctuate depending upon activity
following waking.
3. Insert all probes into the tissue at a depth of .75 cm. Decrease the attenuation of the
ultrasound waves and distance the medication must travel to the collection site to
decrease variance.
4. Increase the sample size. Increased sample size permits greater power in stating results.
5. Utilize a drug with a different molecular size, affecting its ability to pass the stratum
corneum (dexamethasone, lidocaine). Smaller drug molecules may pass the stratum
corneum more easily, thus enabling better evaluation of TDD.
6. Treat each subject’s skin prior to treatment with a thorough cleansing to facilitate more
equality in the stratum corneum. Treating the skin may increase stratum corneum
permeability.
7. Consider performing test with one group receiving an ice treatment prior to application of
ultrasound to limit the drug being carried away prior to reaching the target tissues.
Reduced blood flow to the target tissue may decrease the drug from being “taken up”
superficially into the blood stream once it passes through the stratum corneum layer and
reaching exact target tissues.
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8. Continue to measure and control for muscle depth, collection depth or probe depth, and
pre-cortisol levels. This study has shown they can affect the level of drug delivery, as
well as assist in clarifying post – treatment results.

